Month: September 2026

• Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment
• Data reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration
• Data will be submitted to health authorities and presented at an upcoming medical meeting

Basel, 17 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/Rituxan® (rituximab) plus lenalidomide in people with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one prior line of treatment met its primary endpoint. Results demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS). Overall survival (OS) data were immature at the time of interim analysis. The safety profile of the Lunsumio and lenalidomide combination was consistent with the known profiles of the individual study medicines, with no new safety signals identified. Data from the study will be submitted to health authorities and presented at an upcoming medical meeting.

“People living with relapsed or refractory follicular lymphoma need treatment options that provide meaningful clinical benefit and minimal disruptions to everyday care,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development.  “The CELESTIMO results indicate that a two-drug outpatient Lunsumio regimen may offer these patients an effective new option earlier in their treatment journey.”

CELESTIMO is a confirmatory study required to convert the accelerated approval/conditional marketing authorisation of Lunsumio monotherapy for third-line or later (3L+) FL to full approval, as well as to secure an indication in second-line or later (2L+) FL.

Lunsumio is part of Roche’s industry-leading CD20xCD3 bispecific antibody programme. It is designed with the unique needs and preferences of patients in mind, offering the possibility of outpatient treatment and flexibility between intravenous and subcutaneous administration routes. Lunsumio is already approved for people with 3L+ FL in 60 countries worldwide and has been used to treat over 3,800 patients.¹

With the longest follow-up data of any bispecific antibody in lymphoma and a broad clinical development programme spanning multiple disease settings, including both FL and diffuse large B-cell lymphoma (DLBCL), Lunsumio is helping redefine care across B-cell malignancies. The U.S. Food and Drug Administration (FDA) recently accepted the supplemental Biologics License Application (sBLA) for Lunsumio in combination with Polivy® (polatuzumab vedotin) for 2L+ DLBCL based on the SUNMO study, and results from CELESTIMO support continued expansion of Lunsumio and lenalidomide into earlier FL treatment, with the phase III MorningLyte study ongoing in first-line FL.

About the CELESTIMO study
CELESTIMO [NCT04712097] is a phase III trial evaluating the efficacy and safety of Lunsumio® (mosunetuzumab) in combination with lenalidomide vs. MabThera®/Rituxan® (rituximab) plus lenalidomide in people with relapsed or refractory follicular lymphoma (FL) who have received at least one line of prior systemic therapy. It is a confirmatory study required to convert the accelerated approval/conditional marketing authorisation of Lunsumio monotherapy for third-line or later FL to full approval, as well as to secure an indication in second-line or later FL.

About follicular lymphoma
Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkin lymphoma, accounting for about one in five cases.² It typically responds well to treatment but is often characterised by periods of remission and relapse.³ The disease typically becomes harder to treat each time a patient relapses, and early progression can be associated with poor long-term prognosis.⁴ It is estimated that more than 110,000 people are diagnosed with FL each year worldwide.⁵

About Lunsumio® (mosunetuzumab)
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate malignant B cells. Lunsumio is currently approved as a fixed-duration monotherapy for the treatment of adult patients with third-line or later relapsed or refractory follicular lymphoma (FL) in both intravenous and subcutaneous (Lunsumio VELO™) formulations. A robust, global development programme is ongoing to explore the clinical utility of Lunsumio earlier in the disease course and in novel combinations, including the phase III CELESTIMO trial in second-line or later FL.

About Roche in haematology
Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3. Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Roche data on file.
[2] Lymphoma Research Foundation. About Follicular Lymphoma. [Internet; cited September 2026]. Available from: https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/follicular-lymphoma/
[3] Lymphoma Action. Follicular Lymphoma. [Internet; cited September 2026]. Available from: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma
[4] Skarbnik AZ et al. Treatment selection for patients with relapsed or refractory follicular lymphoma. Front Oncol. 2023;13:1120358.
[5] World Health Organization. Numbers derived from GLOBOCAN 2022. Non-Hodgkin Lymphoma Factsheet [Internet; cited September 2026]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf.

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz Phone: +41 79 529 70 35	Lorena Corfas Phone: +41 79 568 24 95
Simon Goldsborough Phone: +44 797 32 72 915	Karsten Kleine Phone: +41 79 461 86 83
Kirti Pandey Phone: +41 79 398 38 53	Yvette Petillon Phone: +41 79 961 92 50
Irène Stephan Phone:  +41 79 377 83 75	Albert Thottiyil Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

• Media Investor Release Lunsumio CELESTIMO stud_ English

Vancouver, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on humanoid robotics and embodied AI, notes the launch of AutomationFinder.com.au by Robotics Australia Group (“RAG”), Australia’s national peak body for robotics, automation and physical AI. The platform is powered by HowToRobot, a Humanoid Global portfolio company.

Humanoid Global holds a minority equity interest in HowToRobot through its US$75,000 participation in HowToRobot’s Series A financing, announced on February 26, 2026. Humanoid Global also serves on HowToRobot’s advisory board pursuant to a two-year advisory agreement under which it provides strategic advice to HowToRobot for no monetary compensation. Humanoid Global does not control or operate HowToRobot and is not a party to the arrangement between HowToRobot and RAG.

RAG launched AutomationFinder.com.au on September 1, 2026 as a vendor-neutral platform intended to help Australian businesses identify automation opportunities, prepare supplier-ready project briefs, assess feasibility and cost, compare potential solutions and connect with automation providers.

According to RAG, the platform draws on more than 600 real automation projects and combines HowToRobot’s technology and methodology, including its global network of more than 20,000 automation suppliers, of which up to 500 are in Australia, with RAG’s industry knowledge, relationships and local reach. RAG has described the partnership as HowToRobot’s first country-wide licensed deployment.

“We believe a national licence is a meaningful step for HowToRobot,” said Sunny Ray, Chief Executive Officer of Humanoid Global. “Helping a business work out what is worth automating, and who can deliver it, is often the hardest part of adoption. We’re glad to support the HowToRobot team as an investor and advisor.”

-##-

About Humanoid Global Holdings Corp.

Humanoid Global Holdings Corp. (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF) (“Humanoid Global” or the “Company”) is a publicly traded investment issuer building a portfolio of pioneering companies in the growing humanoid robotics and embodied AI sector, investing in and accelerating their growth. It serves as a global investment platform providing liquidity and access to an actively managed portfolio spanning the value chain of this emerging ecosystem, including advanced software, hardware, and enabling technologies. Led by a team with a proven track record of scaling transformative technologies globally, the Company takes a long-term, partnership-oriented approach. It provides capital and strategic consultation on go-to-market strategies, regulatory pathways, and transaction advisory, while facilitating introductions to customers, suppliers, and strategic partners.

Learn more: https://www.humanoidglobal.ai/

For further information, please contact:

Sunny Ray
Chief Executive Officer
finance@humanoidglobal.ai
info@humanoidglobal.ai
(604) 602-0001

CSE:ROBO
OTCQB:RBOHF
FWB:0XM1

ON BEHALF OF MANAGEMENT

Sunny Ray
Chief Executive Officer

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the anticipated adoption, use, development and expansion of AutomationFinder.com.au; the anticipated benefits and functionality of the platform; HowToRobot’s ability to support and expand its licensing model, supplier network and international operations; the anticipated demand for automation planning, sourcing and related services; and the Company’s expectations regarding its investment in and advisory relationship with HowToRobot.

Forward-looking information is based on assumptions that HowToRobot and RAG will continue to operate and support AutomationFinder.com.au substantially as described; that the relationship between HowToRobot and RAG will continue; that market demand for automation-related services will develop as anticipated; and that HowToRobot will have sufficient capital, personnel, technology, suppliers and commercial partners to pursue its business objectives. These assumptions may prove to be incorrect.

The Company holds a minority equity interest in HowToRobot and serves on its advisory board, and therefore has a financial interest in HowToRobot’s success. Readers should consider this interest when evaluating the information in this news release.

Forward-looking information is subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including: the risk that AutomationFinder.com.au may not achieve anticipated user, supplier or commercial adoption; the risk that the platform may not deliver anticipated functionality, benefits or market acceptance; the risk that the relationship between HowToRobot and RAG may be modified, suspended or terminated; risks relating to HowToRobot’s ability to scale its licensing model, platform, supplier network and international operations; technology, cybersecurity, data security and intellectual property risks; the risk that automation projects may not proceed or achieve anticipated benefits; competition; regulatory changes; general economic and market conditions; and risks relating to the Company’s reliance on portfolio companies in which it holds minority interests and over which it has no control.

Additional risks are described in the Company’s public filings available under its profile on SEDAR+ at www.sedarplus.ca. Forward-looking information speaks only as of the date of this news release, and the Company undertakes no obligation to update or revise it except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking information.

Certain information regarding HowToRobot, RAG and AutomationFinder.com.au has been derived from RAG’s September 1, 2026 public announcement and other publicly available materials. Humanoid Global has not independently verified this information. The Company is not the operating company and is not a party to the licensing arrangement, customer relationships or other operating activities described in this news release, and nothing in this news release should be read as suggesting that the Company itself has entered into or achieved any such arrangement.

Wereldhave Belgium sells De Mael retail park in Sint-Kruis (Bruges) and strengthens its financial position

PRESS RELEASE | Vilvoorde, 17 September 2026

Wereldhave Belgium has reached a conditional private sale agreement with a consortium of private investors for the sale of De Mael retail park in Sint-Kruis, Bruges. The transaction is in line with the company’s strategic focus on dominant mid-sized shopping centers in Belgium and Luxembourg.

The selling price amounts to €49.2 million, excluding transfer tax, exceeding the asset’s latest book value. The transaction reflects a net initial yield of 5.6%. The transfer of the asset is expected to take place in the second quarter of 2027 and has no impact on the previously communicated outlook for the 2026 financial year.

Since its acquisition in 2018, De Mael has undergone an extensive transformation, including renovations, investments in sustainability and mobility, and a strengthened tenant mix. Through the sale, Wereldhave Belgium realises the value built up at the site and strengthens its financial position to support further growth and pursue new investment opportunities.

More from Wereldhave Belgium | Latest news

The full press release is available as an attachment.

Attachment

• WHB_Press-release_Sale_DeMael

Not for distribution to U.S. Newswire Services or for dissemination in the United States.

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — Real Estate Split Corp. (TSX: RS and RS.PR.A) (the “Company”), announces that it has filed an Amended and Restated Prospectus Supplement relating to its previously announced overnight treasury offering of class A and preferred shares (the “Class A Shares” and “Preferred Shares”, respectively). The Amended and Restated Prospectus Supplement incorporates DBRS’s September 15, 2026 update to the Preferred Shares’ rating to Pfd-3.

The offering prices remain unchanged at $9.15 per Class A share and $10.45 per preferred share. Gross Proceeds of the Offering are expected to be $21.5 million and the Offering is expected to close on or about Wednesday, September 23, 2026, subject to certain closing conditions, including approval by the Toronto Stock Exchange.

The syndicate of agents for the offering was co-led by CIBC Capital Markets, RBC Capital Markets, and Scotiabank, and included National Bank Financial Inc., Canaccord Genuity Corp., Hampton Securities Limited, BMO Nesbitt Burns Inc., CI Investor Services Inc., iA Private Wealth Inc., Raymond James Ltd., Manulife Wealth Inc., Ventum Financial Corp., Wellington-Altus Private Wealth Inc., Desjardins Securities Inc., and Research Capital Corporation.

For further information, please visit our website at www.middlefield.com or contact our Sales and Marketing Department at 1.888.890.1868.

A short form base shelf prospectus containing important detailed information about the securities being offered has been filed with securities commissions or similar authorities in each of the provinces and territories of Canada. Copies of the short form base shelf prospectus may be obtained from a member of the syndicate. The Company intends to file a supplement to the short form base shelf prospectus, and investors should read the short form base shelf prospectus and the prospectus supplement before making an investment decision. There will not be any sale or any acceptance of an offer to buy the securities being offered until the prospectus supplement has been filed with the securities commissions or similar authorities in each of the provinces and territories of Canada.

Atos partners with GCH to open new AI-Driven Security Operations Center in the UAE

Next Gen Dubai-based SOC supports local data residency, national cyber resilience priorities and faster response to regional and AI- threats

Dubai, United Arab Emirates – September 17, 2026 – Atos, a global leader of AI-powered digital transformation, today announced the opening of its new AI-driven Security Operations Center (SOC) in the United Arab Emirates in partnership with GCH. The new Dubai-based SOC will provide sovereign security operations with local data residency, helping organizations strengthen cyber resilience, address regional and AI-driven threats, and support compliance with UAE Information Assurance Standards and National Electronic Security Authority requirements.

The opening supports the UAE’s national cyber resilience priorities by providing locally operated monitoring, detection and incident response capabilities. The SOC is designed to help government entities, critical infrastructure operators and enterprises, retain greater control over security data and operations within the UAE, while strengthening governance and alignment with local regulatory requirements.

The SOC will use advanced analytics, automation and AI-driven operations to accelerate threat detection, investigation and response. Using Agentic AI to significantly reduce Mean Time to Detect (MTTD) and Mean Time to Respond (MTTR), Atos aims to help customers reduce cyber risk and strengthen overall business resilience as threat actors increasingly use AI to automate and scale attacks.

The UAE SOC will collaborate with the Atos Global Threat Research Center to provide curated threat intelligence informed by global visibility and tailored to the local and regional threat landscape. This approach combines Atos’ international cyber expertise with locally relevant intelligence to support faster and more informed security decisions.

Daniele Principato, head of International Markets, Atos, said: “We are proud to bring AI-powered security operations to the UAE, combining local control with global intelligence in an increasingly complex and fast-evolving threat landscape. Together with GCH, we enable customers to respond faster, safeguard critical operations, and advance their digital sovereignty.”

Surendrasinh Gohil, CEO, Gulf Cyberfender Hub (GCH), said : “The launch a joint UAE Security Operations Center reflects our shared commitment with Atos to supporting the UAE’s vision for digital sovereignty and cyber resilience. By bringing together Atos’ global cybersecurity expertise and GCH’s regional capabilities, we are enabling organizations to benefit from locally hosted, AI-powered security operations that deliver faster threat detection, rapid incident response and enhanced protection against emerging cyber threats.”

Designed to defend against both conventional and AI-driven attacks, the SOC will combine human expertise with AI-enabled detection, investigation and response. Its local operating model and connection to Atos’ global threat research capabilities as well as the Atos Global SOC network will support organizations across the UAE and the wider region as they modernize their security operations and build more resilient digital environments.

***

About Atos

Atos is the Atos Group brand dedicated to AI-powered, secure, end-to-end digital services. Atos designs, develops, and operates critical digital environments that drive performance, resilience and sovereignty, helping public and private organizations worldwide retain control over their data and infrastructures, while meeting regulatory requirements.

With more than 52,000 employees serving over 4,500 clients across 54 countries, Atos helps modernize core IT systems, accelerate cloud and data transformation, strengthen cybersecurity, and deliver secure digital workplace environments to support its clients, its employees and society. Atos also provides consulting and advisory services through its Atos Amplify brand.

A trusted partner in operating complex and mission-critical environments, Atos supports organizations across highly regulated and sovereign contexts.

About Atos Group

Atos Group is a global leader in digital transformation with c. 54,000 employees and annual revenue of c. €7.2 billion, operating in 54 countries under two brands – Atos for services and Eviden for products and systems. European number one in cybersecurity and a leader in cloud, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos Group is listed on Euronext Paris.

About Gulf Cyberfender Hub (GCH)

Gulf Cyberfender Hub (GCH) is a technology consulting and digital solutions company headquartered in Dubai, UAE. GCH is helping enterprises to innovate, automate, optimize and protect their business in the area of Infrastructure Management, Application Management and Cybersecurity. GCH guides enterprises’ digital security architecture during their digital transformation and helps customers understand the cyber security landscape, create a cyber security roadmap that aligns with IT strategy and business goals, and ensure maximum return on their Information Technology Investment. 

Press contact

Lucie.leonardi@atos.ai

Attachments

• Local PR UAE-Atos partners with GCH to open new AI-Driven Security Operations Center in the UAE
• Atos partners with GCH to open new AI-Driven Security Operations Center in the UAE